Author(s):
Naveen K L, Grinton Josvi Veigas, Ananya Bhattacharjee
Email(s):
t.naveen.nulenur@gmail.com
DOI:
10.52711/2231-5713.2021.00023 
Address:
Naveen K L1*, Grinton Josvi Veigas1, Ananya Bhattacharjee2
1Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Mangalore.
1,2Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Mangalore.
*Corresponding Author
Published In:
Volume - 11,
Issue - 2,
Year - 2021
ABSTRACT:
Diabetes mellitus is metabolic disorder characterised by hyperglycaemia of human blood due to inadequate secretion and action of hormone insulin. Different classes of DM are Type-1, Type-2, neonatal, gestational and maturity onset of diabetes at young stage. The main pathologic cause for the DM is autoimmune destruction of ß-cells and insulin deficiency due to resistance of insulin action caused by the abnormalities in metabolism of carbohydrates, protein and lipids which intern cause lack of insulin action on target tissues. Chronic stage of hyperglycaemia is associated with permanent damage, failure and dysfunction of various organs system, which includes heart, blood vessel, eyes, neurones and kidney. Long term DM may causes some health complications in patient such as nephropathy, neuropathy, retinopathy and other complications like peripheral vasculopathy and ischemia of heart. In current era ocular complications associated with DM are rapid and progressive, becoming world top most cause of morbidity. This article covers brief information regarding ocular complications and vision loss in patient with DM.
Cite this article:
Naveen K L, Grinton Josvi Veigas, Ananya Bhattacharjee. Patient with Diabetes Mellitus and Ocular Complications: A Brief review. Asian Journal of Pharmacy and Technology. 2021; 11(2):141-5. doi: 10.52711/2231-5713.2021.00023
Cite(Electronic):
Naveen K L, Grinton Josvi Veigas, Ananya Bhattacharjee. Patient with Diabetes Mellitus and Ocular Complications: A Brief review. Asian Journal of Pharmacy and Technology. 2021; 11(2):141-5. doi: 10.52711/2231-5713.2021.00023 Available on: https://ajptonline.com/AbstractView.aspx?PID=2021-11-2-8
REFERENCE:
1. Sicree R, Shaw J and Zimmet P. The Global Burden of Diabetes. Diabetes and Impaired Glucose Tolerance: Prevalence and Projection. In: Delice Gan, Editors. Diabetic Atlas. 2nd edition, Brussels; International Diabetic Federation, 2006. pp.16-103.
2. Tripathi KD. Essential of medical pharmacology. 6th edition. Jaypee Brother’s medical publishers (p) Ltd. New Delhi; 2006: pp. 254.
3. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on anti-diabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed. 2012 Apr;2(4):320.
4. Piero MN, Nzaro GM, Njagi JM. Diabetes mellitus-a devastating metabolic disorder. Asian j. biomed. pharm. sci. 2015 Jan 1;5(40):1-4.
5. Elvin-Lewis M, should we have concerned about herbal remedies. J Ethnopharmacol. 2001 May;75(2-3):141-64.
6. Patel K, Srinivasan K, Plant foods in the management of diabetes mellitus: vegetables as potential hypoglycemic agents. Nahrung. 1997Apr;41(2);68-74.
7. Kamtekar S, Keer V. Management of Diabetes: A Review. Diabetes. 2014 Sep 29;7(9): 1065-1072.
8. Sapra A, Bhandari P. Diabetes Mellitus. 2021 Feb 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 31855345.
9. S.V. Rupashri, Gheena. S. Recent Advances in Diabetes Research. Research J. Pharm. and Tech 2016; 9(10):1806-1808.
10. Nandhini Murali, Abinaya S.K, Saveetha. V. Knowledge, attitude and practice of Diabetic Retinopathy among type II diabetic patients of South Indian population. Research J. Pharm. and Tech. 2017; 10(9): 3017-3021
11. M. Sujatha Kumari, M. Kiran Babu, Rehana Sulthana, M. Srinivas, Ch. Prasanthi. Diabetes Mellitus: Present status and Drug therapy Updates. Research J. Pharm. and Tech. 7(1): Jan. 2014; Page 84-94.
12. Singh PP, Mahadi F, Roy A, Sharma P. Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2. Indian journal of clinical Biochemistry. 2009 Oct 1;24(4):324-42.
13. Samidha Kamtekar, Vrushali Keer. Management of Diabetes: A Review. Research J. Pharm. and Tech. 7(9): Sept. 2014 Page 1065-1072.
14. Singh PP, Mahadi F, Roy A, Sharma P. Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2. Indian journal of clinical Biochemistry. 2009 Oct 1;24(4):324-42.
15. Vieira-Potter VJ, Karamichos D, Lee DJ. Ocular complications of diabetes and therapeutic approaches. BioMed research international. 2016 Oct; 1-14.
16. Milana V. Dunaieva, Oleksii V. Pohorielov, Yulia V. Getman, Kateryna V. Mizyakina, Ziwei Wang. New Approaches to Neurophysiological Diagnosis and Treatment of Diabetic Vitreal Hemorrhages. Research J. Pharm. and Tech. 2019; 12(12): 5723-5728.
17. R. Simó and C. Hernández, “Advances in the medical treatment of diabetic retinopathy,” Diabetes Care, 2009 Aug; 32(8):1556–1562.
18. Centers for Disease Control and Prevention. Diabetes Data and Trends. Available at: http://www.cdc.gov/diabetes/statistics/newDataTrends.htm Accessed Mar 24, 2021.
19. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Physical therapy. 2008 Nov 1;88(11):1254-64.
20. Browning DJ, Stewart MW, Lee C. Diabetic macular edema: evidence-based management. Indian journal of ophthalmology. 2018 Dec;66(12):1736.
21. Wenick AS, Bressler NM. Diabetic macular edema: current and emerging therapies. Middle East African journal of ophthalmology. 2012 Jan;19(1):4.
22. Al-Dhibi H, Khan AO. Response of diabetic papillopathy to intravitreal bevacizumab. Middle East African journal of ophthalmology. 2011 Jul;18(3):243.
23. Yildirim M, Kilic D, Dursun ME, Dursun B. Diabetic papillopathy treated with intravitreal ranibizumab. International medical case reports journal. 2017; 10:99.
24. Zhao YX, Chen XW. Diabetes and risk of glaucoma: systematic review and a Meta-analysis of prospective cohort studies. International journal of ophthalmology. 2017;10(9):1430.
25. Song BJ, Aiello LP, Pasquale LR. Presence and risk factors for glaucoma in patients with diabetes. Current diabetes reports. 2016 Dec;16(12):1-3.
26. Tripathi S, Srinivasan M. Glaucoma and diabetes: A review. Indian Journal of Clinical and Experimental Ophthalmology. 2018 Jul;4(3):294-9.
27. Javadi MA, Zarei-Ghanavati S. Cataracts in diabetic patients: a review article. Journal of ophthalmic & vision research. 2008 Jan;3(1):52.
28. Pollreisz A, Schmidt-Erfurth U. Diabetic cataract—pathogenesis, epidemiology and treatment. Journal of ophthalmology. 2010 Oct;2010:1-8.
29. Kiziltoprak H, Tekin K, Inanc M, Goker YS. Cataract in diabetes mellitus. World journal of diabetes. 2019 Mar 15;10(3):140.
30. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007).Ocul Surf. 2007 Apr; 5(2):75-92
31. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995; 21:221–232.
32. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003; 136:318–326.
33. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Arch Ophthalmol. 2009; 127:763–768.
34. Kaji Y, Usui T, Oshika T, Matsubara M, Yamashita H, Araie M, Murata T, Ishibashi T, Nagai R, Horiuchi S, et al. Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci. 2000; 41:362–368.
35. Kinoshita JH, Fukushi S, Kador P, Merola LO. Aldose reductase in diabetic complications of the eye. Metabolism. 1979; 28:462–469.
36. Schultz RO, Van Horn DL, Peters MA, Klewin KM, Schutten WH Trans Am Ophthalmol Soc. 1981; 79():180-99.
37. Corneal epithelial fragility in diabetes mellitus. Saini JS, Khandalavla B. Can J Ophthalmol. 1995 Apr; 30(3):142-6.
38. Awata T, Sogo S, Yamagami Y, Yamamoto Y. Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. J Ocul Pharmacol. 1988; 4:195–201.
39. Tao JH, Barbi J, Pan F. Hypoxia-inducible factors in T lymphocyte differentiation and function. A review in the theme: cellular responses to hypoxia. American Journal of Physiology-Cell Physiology. 2015 Nov 1;309(9):C580-9.